Welcome to our dedicated page for Morphosys news (Ticker: MOR), a resource for investors and traders seeking the latest updates and insights on Morphosys stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Morphosys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Morphosys's position in the market.
MorphoSys AG (FSE:MOR) and Incyte announced that Monjuvi (tafasitamab-cxix) is now included in the NCCN Guidelines for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) with a Category 2A designation. This designation applies to adult patients who have previously received treatment and are ineligible for autologous stem cell transplant. Monjuvi, approved by the FDA on July 31, 2020, offers a much-needed option for patients with limited treatments. Approximately 10,000 patients in the U.S. are diagnosed annually with this condition.